nevirapine has been researched along with rifampin in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 25 (43.86) | 29.6817 |
| 2010's | 28 (49.12) | 24.3611 |
| 2020's | 3 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Banerjee, D; Bhat, P; Sriram, D; Srividya, M; Thomas, A; Yogeeswari, P | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Back, DJ; de Ruiter, A; Dean, GL | 1 |
| Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I | 1 |
| Casas, E; Mariño, A; Molina, JA; Moreno, S; Oliva, J; Ribera, E; Rubio, R; Sanz, J | 1 |
| Friedland, GH | 1 |
| Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW | 1 |
| Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Raja, K; Rajasekaran, S; Ramachandran, G; Sathishnarayan, S; Sukumar, B; Swaminathan, S | 1 |
| Chaovavanich, A; Likanonsakul, S; Manosuthi, W; Prasithsirikul, W; Rattanasiri, S; Ruxrungtham, K; Sungkanuparph, S; Thakkinstian, A | 1 |
| Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S | 1 |
| Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE | 1 |
| Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S | 1 |
| Gibbins, S; Kon, O; O'Donoghue, M; Obiorah, I; Sathia, L; Taylor, G; Walsh, J; Winston, A | 1 |
| Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H | 1 |
| Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G | 1 |
| Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Pozniak, A; Sabin, C; Stöhr, W; Winston, A | 1 |
| Likanonsakul, S; Manosuthi, W; Prasithisirikul, W; Sungkanuparph, S; Tantanathip, P | 1 |
| Lalloo, UG | 1 |
| Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S | 1 |
| Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P | 1 |
| Chang, SY; Hung, CC; Lin, SW | 1 |
| Kwara, A; Ramachandran, G; Swaminathan, S | 1 |
| Bauerfeind, A; Foncha, C; Harries, AD; Kwanjana, J; Manzi, M; Misinde, D; Moses, M; Mwagomba, B; Tayler-Smith, K; Zachariah, R | 1 |
| Disratthakit, A; Doi, N; Ohta, Y; Takenaga, M | 1 |
| Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S | 1 |
| Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M | 1 |
| Badiane, CI; Batista, G; Bazolo, N; Guèye, NF; Manga, NM; Poda, A; Sané, O; Sow, PS | 1 |
| Chaddha, U; Goray, A; Kumar, AK; Lala, M; Ramachandran, G; Shah, I; Swaminathan, S; Tayal, S | 1 |
| Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W | 1 |
| Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N | 1 |
| Manosuthi, W; Wongsawat, J | 1 |
| Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS | 1 |
| Nugroho, AW; Wiria, MS; Yunihastuti, E | 1 |
| Khusmith, S; Likanonsakul, S; Manosuthi, W; Shioda, T; Uttayamakul, S; Wichukchinda, N | 1 |
| Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C | 1 |
| Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S | 1 |
| Chandrasekharan, C; Kumar, AK; Ponnuraja, C; Rajesh, L; Ramachandran, G; Ramesh, K; Swaminathan, S | 1 |
| Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM | 1 |
| Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN | 1 |
| Chaisson, RE; Cohn, S; Denti, P; Dooley, KE; Hoffmann, JD; Lala, SG; Martinson, N; Mashabela, F; McIlleron, H; Msandiwa, R; Shembe, S; Velaphi, S; Wiesner, L | 1 |
| Baker, P; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Haas, DW; Mohapi, L; Mwelase, N; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Langat, D; Mohapi, L; Mwelase, N; Omoz-Oarhe, A; Pham, MM; Podany, AT; Samaneka, W; Supparatpinyo, K; Swindells, S | 1 |
3 review(s) available for nevirapine and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2010 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Coinfection; Cyclopropanes; HIV Infections; Humans; Nevirapine; Rifampin; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
13 trial(s) available for nevirapine and rifampin
| Article | Year |
|---|---|
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis | 2008 |
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Thailand; Treatment Outcome; Tuberculosis | 2008 |
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Computer Simulation; Cross-Sectional Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nevirapine; Nonlinear Dynamics; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Young Adult | 2009 |
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Plasma; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load | 2009 |
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Plasma; Rifampin; Time Factors; Tuberculosis; Uganda | 2011 |
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Liver Function Tests; Logistic Models; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; Thailand; Tuberculosis; Young Adult | 2011 |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Rifampin; Stavudine; Treatment Outcome; Tuberculosis; Zambia | 2012 |
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nevirapine; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Rifampin; Thailand; Tuberculosis; Viral Load | 2012 |
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Nevirapine; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Viral Load | 2013 |
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Pilot Projects; Rifampin; Tuberculosis | 2013 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Young Adult | 2014 |
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Drug Synergism; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Pharmacogenetics; Rifampin; Young Adult | 2021 |
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Rifampin; Young Adult | 2021 |
41 other study(ies) available for nevirapine and rifampin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; Isocitrate Lyase; Models, Molecular; Molecular Conformation; Mycobacterium tuberculosis; Thiosemicarbazones; Tuberculosis | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effect of tuberculosis therapy on nevirapine trough plasma concentrations.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Drug Interactions; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary | 1999 |
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Chromatography, High Pressure Liquid; Drug Interactions; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis | 2001 |
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Rifampin; Treatment Outcome; Tuberculosis | 2003 |
Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.
Topics: Brazil; Congresses as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis | 2005 |
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Female; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Rifampin; Thailand; Tuberculosis | 2005 |
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2006 |
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Nevirapine; Prospective Studies; Rifampin; Treatment Outcome; Tuberculosis | 2006 |
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis | 2007 |
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Malawi; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Stavudine; Treatment Outcome; Tuberculosis | 2007 |
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Rifampin; South Africa; Tuberculosis | 2008 |
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin; South Africa; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Viral Load; White People | 2008 |
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Rifampin; RNA, Viral; Stavudine; Thailand; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis | 2009 |
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Prospective Studies; Rifampin; Stavudine; Tuberculosis | 2009 |
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis | 2009 |
Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Malawi; Male; Nevirapine; Retrospective Studies; Rifampin; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2010 |
Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model.
Topics: Administration, Intranasal; Animals; Antibiotics, Antitubercular; Drug Interactions; Female; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Microspheres; Models, Animal; Nevirapine; Reference Standards; Rifampin; Tuberculosis | 2010 |
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confidence Intervals; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Nevirapine; Prospective Studies; Rifampin; RNA, Viral; Thailand; Treatment Outcome; Tuberculosis; Viral Load | 2010 |
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromatous; Neuritis; Nevirapine; Rifampin; Senegal; Stavudine; Tinea Capitis | 2011 |
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin | 2011 |
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
Topics: Administration, Oral; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Plasma; Rifampin; Tuberculosis | 2012 |
Treatment challenges in co-infected HIV and TB children.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin | 2011 |
Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2012 |
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2013 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Isoniazid; Male; Mothers; Nevirapine; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Rifampin; Tuberculosis | 2017 |
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Isoniazid; Nevirapine; Rifampin | 2022 |